Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,895 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SpDamID: Marking DNA Bound by Protein Complexes Identifies Notch-Dimer Responsive Enhancers.
Hass MR, Liow HH, Chen X, Sharma A, Inoue YU, Inoue T, Reeb A, Martens A, Fulbright M, Raju S, Stevens M, Boyle S, Park JS, Weirauch MT, Brent MR, Kopan R. Hass MR, et al. Among authors: stevens m. Mol Cell. 2015 Aug 20;59(4):685-97. doi: 10.1016/j.molcel.2015.07.008. Epub 2015 Aug 6. Mol Cell. 2015. PMID: 26257285 Free PMC article.
A review of toxicology studies on cyanurate and its chlorinated derivatives.
Hammond BG, Barbee SJ, Inoue T, Ishida N, Levinskas GJ, Stevens MW, Wheeler AG, Cascieri T. Hammond BG, et al. Among authors: stevens mw. Environ Health Perspect. 1986 Nov;69:287-92. doi: 10.1289/ehp.8669287. Environ Health Perspect. 1986. PMID: 3545805 Free PMC article. Review.
Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial.
Balevic SJ, Benjamin DK Jr, Powderly WG, Smith PB, Gonzalez D, McCarthy MW, Shaw LK, Lindsell CJ, Bozzette S, Williams D, Linas BP, Blamoun J, Javeri H, Hornik CP; ACTIV-1 IM Study Group. Balevic SJ, et al. JAMA Netw Open. 2024 Apr 1;7(4):e247615. doi: 10.1001/jamanetworkopen.2024.7615. JAMA Netw Open. 2024. PMID: 38662372 Clinical Trial.
CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.
Ferrero F, Lin CY, Liese J, Luz K, Stoeva T, Nemeth A, Gijón M, Calvo C, Natalini S, Toh TH, Deleu S, Chen B, Rusch S, Sánchez BL, Leipoldt I, Vijgen L, Huntjens D, Baguet T, Bertzos K, Gamil M, Stevens M; CROCuS Investigators. Ferrero F, et al. Among authors: stevens m. Paediatr Drugs. 2024 Apr 22. doi: 10.1007/s40272-024-00625-x. Online ahead of print. Paediatr Drugs. 2024. PMID: 38649595
3,895 results